Oncology Reviews

, Volume 1, Issue 3, pp 141–151

Bisphosphonates: from preclinical evidence to survival data in the oncologic setting

Authors

    • Medical OncologyUniversity Campus Bio-Medico
  • Sara Galluzzo
    • Medical OncologyUniversity Campus Bio-Medico
  • Maria Elisabetta Fratto
    • Medical OncologyUniversity Campus Bio-Medico
  • Bruno Vincenzi
    • Medical OncologyUniversity Campus Bio-Medico
  • Silvia Angeletti
    • Clinical PathologyUniversity Campus Bio-Medico
  • Giordano Dicuonzo
    • Clinical PathologyUniversity Campus Bio-Medico
  • Gaia Schiavon
    • Medical OncologyUniversity Campus Bio-Medico
  • Giuseppe Tonini
    • Medical OncologyUniversity Campus Bio-Medico
Review

DOI: 10.1007/s12156-007-0017-1

Cite this article as:
Santini, D., Galluzzo, S., Fratto, M.E. et al. Oncol Rev (2007) 1: 141. doi:10.1007/s12156-007-0017-1
  • 17 Views

Abstract

Bisphosphonate therapy has become a standard of therapy for patients with malignant bone disease. In vivo pre-clinical data suggest that bisphosphonates may exert an antitumor effect and preliminary clinical data show promising activity on metastatic disease in cancer patients. This review will describe the pre-clinical evidence of action of bisphosphonates on osteoclasts and tumor cells, in both in vitro and animal models. In addition, the effects of principal bisphosphonates on skeletal disease progression in patients with cancers in different sites, including breast cancer, prostate cancer and non-small cell lung cancer will be reported. The preliminary clinical data from retrospective trials on the effect of bisphosphonates on survival will be described and the ongoing adjuvant phase III trial will be analyzed. This review will describe the preliminary clinical evidences from prospective studies on the effect of zoledronic acid treatment on the prevention of bone metastases.

Key words

BisphosphonatesBone metastasesSurvivalPreclinical

Copyright information

© Springer 2007